Johnson & Johnson JNJ and Pfizer PFE rank among the world’s largest pharmaceutical companies, each with broad and diversified ...

Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment ...

Pfizer's CEO said President Donald Trump's tariffs and uncertainty are holding the company back from making "tremendous investments" in the US. In a first-quarter earnings call on Tuesday, chief ...

Pfizer (NYSE:PFE) experienced a 2.98% price move over the past month, coinciding with new strategic collaborations. Notably, ...

Pfizer shares currently trade at approximately $23, down 13% year-to-date and significantly below their 2021 peak of around $60. The company experienced extraordinary growth during the COVID-19 ...

Pfizer's CEO, Albert Bourla, said tariffs are preventing the company from making "tremendous investments" in the US. Leigh Vogel/Getty Images for Concordia Summit 2025-04-30T04:30:53Z ...

Pfizer's Hympavzi showed superior bleed control in hemophilia A and B patients with inhibitors, reducing bleeding rates and ...

After the deal closes, which is expected to occur in the third quarter, Pfizer will make a $100 million equity investment in 3Sbio. To put Pfizer's deal in perspective, rival Merck & Co. Inc. (MRK ...

Pharmaceutical stocks, including Pfizer (NYSE: PFE), have recently been scrutinized after President Trump’s executive order instructing drug manufacturers to reduce medicine prices to align with ...

Upon the deal’s close, Pfizer will make the $100 million equity investment in 3SBio, according to the agreement. 3SBio could receive up to an additional $4.8 billion if the drug achieves milestones.